Integra Lifesciences Holdings Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
8.5%projected annual EPS growth
Analyst Coverage
9analysts covering
FY Revenue (est.)
$1.7Bnext fiscal year
FY EPS (est.)
$2.46next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 4 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Organic Revenue Growth Quarterly130.0%Target: 0.8% to 3.3%
Adjusted Gross Margin Quarterly6,410.0%Target: Expansion through operational transformation
Adjusted EBITDA Margin Quarterly1,940.0%Target: Improvement via structural optimization
Watch Items
- Braintree Manufacturing Facility Production and SurgiMend RelaunchTrigger: Production start by end of June 2026; launch in Q4 2026Action: Monitor progress updates in Q2 and Q3 2026 earnings calls to ensure timeline compliance.
- FDA Quality System Commitments and Warning Letter ResolutionTrigger: Ongoing compliance audits and remediation costsAction: Track regulatory filings and corporate updates regarding the status of the December 2024 warning letter.
- Leverage Ratio ReductionTrigger: Consolidated total leverage ratio of 4.1x as of Q1 2026Action: Evaluate progress toward the target leverage range of 2.5x to 3.5x by the end of 2026.
Research as of 19 Jun 2026